Biotherapy Services Limited (BTS) receive a follow-on investment of £1.5m continued support of ongoing clinical trials for its regenerative wound care treatment. The funds will be used to support the clinical development of their patented treatment for Diabetic Foot Ulcers (“DFUs”). Diabetes affects 3.7m people...
Delveinsight Report names Biotherapy Services as one of the innovators in market sector set to increase by 14.1% by 2030 Healthcare and market research consultant, Delveignsight, released an analysis of the global DFU (Diabetic Foot Ulcer) market, naming Biotherapy Services as one of the key...
BIOTHERAPY SERVICES AWARDED INNOVATION PASSPORT FOR GROUNDBREAKING TREATMENT FOR DIABETIC FOOT ULCERS. WINDSOR, April 8, 2021 – Biotherapy Services Ltd (BTS), a clinical stage pharmaceutical biotechnology company developing novel autologous therapies for complex and chronic wounds, has been awarded the innovative medicine designation – the Innovation...
16th February 2021 - Biotherapy Services Ltd re-open trial to recruitment at Loughborough Hospital. Amidst difficult times, BTS are pleased to announce the RAPID-1 DFU clinical trial is open to recruitment at the Loughborough site. Working throughout the past year BTS has established a working partnership...
Biotherapy Services Ltd. welcome Jo Briggs to the team. Joanne Briggs is joining BTS as our new Senior Specialist Consultant. Biotherapy Services Ltd are an established Clinical-Pharmaceutical-Biotech company providing specialist point of care technology and regenerative services to Specialist surgeons, using autologous biologics and treatments which are...